[HTML][HTML] Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection
B Zhang, S Liu, T Tan, W Huang, Y Dong, L Chen… - Chest, 2020 - Elsevier
As of March 24, 2020, novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) has been responsible for 379,661 infection cases with 16,428 deaths globally, and the …
2) has been responsible for 379,661 infection cases with 16,428 deaths globally, and the …
[HTML][HTML] Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19
L Zhang, R Pang, X Xue, J Bao, S Ye, Y Dai… - Aging (Albany …, 2020 - ncbi.nlm.nih.gov
Background: Anti-SARS-CoV-2 virus antibody levels in convalescent plasma (CP), which
may be useful in severe Anti-SARS-CoV-2 virus infections, have been rarely reported …
may be useful in severe Anti-SARS-CoV-2 virus infections, have been rarely reported …
Certainty of success: three critical parameters in coronavirus vaccine development
DC Kaslow - npj Vaccines, 2020 - nature.com
Vaccines for 17 viral pathogens have been licensed for use in humans. Previously, two
critical biological parameters of the pathogen and the host–pathogen interaction …
critical biological parameters of the pathogen and the host–pathogen interaction …
Passive immunotherapies for the next influenza pandemic
Influenzavirus is among the most relevant candidates for a next pandemic. We review here
the phylogeny of former influenza pandemics, and discuss candidate lineages. After briefly …
the phylogeny of former influenza pandemics, and discuss candidate lineages. After briefly …
Long-term clinical prognosis of human infections with avian influenza A (H7N9) viruses in China after hospitalization
Q Wang, H Jiang, Y Xie, T Zhang, S Liu, S Wu… - …, 2020 - thelancet.com
ABSTRACT Background Mainland China has experienced five epidemics of human cases of
avian influenza A (H7N9) virus infection since 2013. We conducted a prospective study to …
avian influenza A (H7N9) virus infection since 2013. We conducted a prospective study to …
Analysis of the dynamics of SI-SI-SEIR Avian influenza A (H7N9) epidemic model with re-infection
The spread of Avian influenza in Asia, Europe and Africa ever since its emergence in 2003,
has been endemic in many countries. In this study, a non-linear SI-SI-SEIR Mathematical …
has been endemic in many countries. In this study, a non-linear SI-SI-SEIR Mathematical …
[HTML][HTML] Preservation of anti-SARS-CoV-2 neutralising antibodies in convalescent plasma after pathogen reduction with methylene blue and visible light
L Larrea, E Castro, L Navarro, B Vera… - Blood …, 2022 - ncbi.nlm.nih.gov
Background COVID-19 convalescent plasma (CCP) is an experimental treatment against
SARS-CoV-2. Although there has so far been no evidence of transmission through …
SARS-CoV-2. Although there has so far been no evidence of transmission through …
[HTML][HTML] Detection and Phylogenetic Characterization of Influenza D in Swedish Cattle
I Alvarez, F Banihashem, A Persson, E Hurri, H Kim… - Viruses, 2024 - mdpi.com
Increased evidence suggests that cattle are the primary host of Influenza D virus (IDV) and
may contribute to respiratory disease in this species. The aim of this study was to detect and …
may contribute to respiratory disease in this species. The aim of this study was to detect and …
[HTML][HTML] Human antibody recognition of H7N9 influenza virus HA following natural infection
IM Gilchuk, S Bangaru, N Kose, RG Bombardi… - JCI insight, 2021 - ncbi.nlm.nih.gov
Avian H7N9 influenza viruses cause sporadic outbreaks of human infections and threaten to
cause a major pandemic. The breadth of B cell responses to natural infection and the …
cause a major pandemic. The breadth of B cell responses to natural infection and the …
Statement–Protocol for the Reconnection of Cardiology Services with Patients During the COVID-19 Pandemic–2020
MS Bittencourt, G Generoso, PHM Melo… - Arquivos brasileiros de …, 2020 - SciELO Brasil
FINANCIAL DECLARATION A-ECONOMICALLY RELEVANT PAYMENTS OF ANY KIND
MADE TO (i) YOU,(ii) YOUR SPOUSE/PARTNER OR ANY OTHER PERSON LIVING WITH …
MADE TO (i) YOU,(ii) YOUR SPOUSE/PARTNER OR ANY OTHER PERSON LIVING WITH …